Northland Capmk Decreases Earnings Estimates for Alvotech

Alvotech (NASDAQ:ALVO) – Northland Capmk dropped their FY2025 earnings estimates for Alvotech in a report released on Thursday, April 10th. Northland Capmk analyst C. Byrnes now expects that the company will earn $0.00 per share for the year, down from their previous estimate of $0.05. The consensus estimate for Alvotech’s current full-year earnings is ($0.07) per share.

Separately, UBS Group began coverage on shares of Alvotech in a report on Friday, February 14th. They issued a “buy” rating and a $18.00 price objective for the company.

Alvotech Stock Up 0.8 %

NASDAQ:ALVO opened at $8.60 on Monday. The firm’s fifty day simple moving average is $10.82 and its 200 day simple moving average is $11.93. The stock has a market cap of $2.59 billion, a P/E ratio of -4.65 and a beta of -0.05. Alvotech has a twelve month low of $7.35 and a twelve month high of $14.76.

Alvotech (NASDAQ:ALVO) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.50. The business had revenue of $153.34 million for the quarter, compared to the consensus estimate of $97.99 million.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of Alvotech by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 3,196,923 shares of the company’s stock valued at $40,905,000 after purchasing an additional 23,799 shares during the last quarter. PointState Capital LP raised its position in shares of Alvotech by 64.1% in the 4th quarter. PointState Capital LP now owns 1,241,379 shares of the company’s stock worth $16,423,000 after purchasing an additional 484,826 shares during the last quarter. Geode Capital Management LLC increased its stake in Alvotech by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 217,587 shares of the company’s stock valued at $2,879,000 after purchasing an additional 8,330 shares in the last quarter. Royce & Associates LP raised its holdings in Alvotech by 21.4% in the fourth quarter. Royce & Associates LP now owns 159,000 shares of the company’s stock worth $2,104,000 after buying an additional 28,000 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Alvotech in the fourth quarter worth approximately $748,000.

Alvotech Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.